Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $74.6 million.

  • Entrada Therapeutics' Non-Current Assets fell 1637.33% to $74.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.8 million, marking a year-over-year decrease of 1427.54%. This contributed to the annual value of $86.3 million for FY2024, which is 1321.55% down from last year.
  • Entrada Therapeutics' Non-Current Assets amounted to $74.6 million in Q3 2025, which was down 1637.33% from $79.6 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Non-Current Assets peaked at $103.8 million during Q2 2023, and registered a low of $39.7 million during Q3 2022.
  • Moreover, its 4-year median value for Non-Current Assets was $83.3 million (2025), whereas its average is $74.4 million.
  • In the last 5 years, Entrada Therapeutics' Non-Current Assets soared by 15670.78% in 2023 and then plummeted by 1637.33% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Non-Current Assets (Quarter) stood at $42.2 million in 2022, then surged by 135.7% to $99.4 million in 2023, then decreased by 13.22% to $86.3 million in 2024, then fell by 13.49% to $74.6 million in 2025.
  • Its last three reported values are $74.6 million in Q3 2025, $79.6 million for Q2 2025, and $83.3 million during Q1 2025.